Silver Book Fact

After one year, 73 percent of non-small-cell lung cancer patients with the EGFR genetic mutation who were treated with a tyrosine kinase inhibitor had survived, compared to 15 percent who received traditional chemotherapy.

Aspinall, M and R Hamermesh. Realizing the Promise of Personalized Medicine. Harvard Bus Rev. 2007; 85(10): 108-17. https://hbr.org/2007/10/realizing-the-promise-of-personalized-medicine

Reference

Title
Realizing the Promise of Personalized Medicine
Publication
Harvard Bus Rev
Publication Date
2007
Authors
Aspinall, M and R Hamermesh
Volume & Issue
Volume 85, Issue 10
Pages
108-17
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Five-year Relative Survival (%) during Three Time Periods by Cancer Site  
  • Use of an epidermal growth factor inhibitor in the treatment of metastatic colon cancer patients without the KRAS gene mutation saw survival rates of 15.6 months, compared to 5.6 months…  
  • Cancer mortality declined more than 2% in 2003, a continuation of the decline that began in 1990.  
  • Percentage of women age 50 and over who had a mammogram in the past 2 years, by age group, selected years 1987-2005  
  • Since the war on cancer was declared in 1971, our arsenal has tripled. New drugs accounted for around 50-60% of the increase in six-year cancer survival rates since 1975.…